The estimated Net Worth of Roger Pomerantz is at least $3.45 Millón dollars as of 7 September 2018. Roger Pomerantz owns over 1,810 units of ContraFect Corp stock worth over $49,600 and over the last 10 years he sold CFRX stock worth over $1,521,173. In addition, he makes $1,875,610 as Chairman of the Board y Chief Executive Officer at ContraFect Corp.
Roger has made over 23 trades of the ContraFect Corp stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 1,810 units of CFRX stock worth $16,290 on 7 September 2018.
The largest trade he's ever made was exercising 160,965 units of ContraFect Corp stock on 18 May 2016 worth over $114,285. On average, Roger trades about 26,835 units every 21 days since 2014. As of 7 September 2018 he still owns at least 213,976 units of ContraFect Corp stock.
You can see the complete history of Roger Pomerantz stock trades at the bottom of the page.
Dr. Roger J. Pomerantz M.D. serves as Chairman of the Board, Chief Executive Officer of the Company. Prior to that, he had served as Vice Chairman of our board of directors since May 2014. From November 2013 to December 2019, Dr. Pomerantz served as Chairman of the board of directors of Seres Therapeutics, Inc., a biotechnology company, and as its President and Chief Executive Officer from June 2014 to January 2019. From 2011 to 2013, he was formerly Worldwide Head of Licensing & Acquisitions, Senior Vice President at Merck & Co., Inc. where he oversaw all licensing and acquisitions at Merck Research Laboratories. Previously, he served as Senior Vice President and Global Franchise Head of Infectious Diseases at Merck. Prior to joining Merck, Dr. Pomerantz was Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals. He joined Johnson & Johnson in 2005 as President of Tibotec Pharmaceuticals, Inc. Dr. Pomerantz serves as Chairman of the board of directors of the public company Collplant Biotechnologies, Inc., a board member of the public company Intec Therapeutics, Inc., Chairman of the board of directors of the private company Silicon Therapeutics Inc. and a member of the board of the private company X-VAX Technology, Inc. Dr. Pomerantz received his B.A. in Biochemistry at the Johns Hopkins University and his M.D. at the Johns Hopkins School of Medicine. He received post-graduate training at the Massachusetts General Hospital, Harvard Medical School and M.I.T. Dr. Pomerantz is Board Certified in both Internal Medicine and Infectious Diseases. He was Professor of Medicine, Biochemistry and Molecular Pharmacology, Chief of Infectious Diseases, and the Founding Director and Chair of the Institute for Human Virology and Biodefense at the Thomas Jefferson University and Medical School.
As the Chairman of the Board y Chief Executive Officer of ContraFect Corp, the total compensation of Roger Pomerantz at ContraFect Corp is $1,875,610. There are no executives at ContraFect Corp getting paid more.
Roger's mailing address filed with the SEC is C/O CONTRAFECT CORPORATION, 28 WELLS AVENUE, 3RD FLOOR, YONKERS, NY, 10701.
Over the last 10 years, insiders at ContraFect Corp have traded over $2,523,392 worth of ContraFect Corp stock and bought 525,578 units worth $426,359 . The most active insiders traders include Sol J Barer, Roger Pomerantz y Industrial Co., Ltd Fosun. On average, ContraFect Corp executives and independent directors trade stock every 70 days with the average trade being worth of $16,159. The most recent stock trade was executed by Michael Messinger on 13 December 2019, trading 5,000 units of CFRX stock currently worth $1,850.
we are a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, particularly those treated in hospital-based settings. due to drug-resistant and newly-emerging pathogens, infections in the hospital are already the fourth leading cause of death in the united states, following heart disease, cancer and stroke. we address multi-drug resistant infections using our therapeutic products from our lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. our strategy is to use our first in class therapies to achieve a leadership position in the treatment of life-threatening infectious diseases, including drug-resistant pathogens. we plan to pursue commercialization of therapeutic products through discovery, acquisition and development of protein and antibody products. our novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills ba
ContraFect Corp executives and other stock owners filed with the SEC include: